Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
about
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic reviewNovel implications in the treatment of hepatocellular carcinoma.Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study.A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.Characterization of the Immune Microenvironment in Hepatocellular Carcinoma (HCC).Lymphoepithelioma-like hepatocellular carcinoma: A case report and brief review of literature.Treatment options after sorafenib failure in patients with hepatocellular carcinoma.Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells.Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.Immune checkpoint therapy in liver cancer.Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.Changing role of histopathology in the diagnosis and management of hepatocellular carcinomaClinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
P2860
Q33648598-9ABD51E8-5323-411A-93A6-C8C0889BA885Q33736377-32C20187-4C7B-45FD-ADC5-872529D2B15FQ33761739-10844651-32E0-4FD7-9EE7-7ABFB702E7DAQ37542835-A3E22C22-9B0E-4EF6-A665-02A9BCEA224DQ37573772-2E00CCA1-2212-43C2-9F8B-0569F72D8B73Q37705021-84312F1D-C9EA-4FB0-A4C1-7A18FBA4538CQ38610333-4C62843C-6A33-4B8D-B648-35EF09A3EB09Q38610336-3B17EBF9-8500-4CC5-B3FA-BB5037D5C6C1Q40069479-14F56A76-43A9-4A8B-86D5-B8A9715CE55EQ41472059-99C2924A-16D2-4CF3-A782-C746A70D059CQ41612927-2D7F3F98-BB83-40A8-A97E-7930887293A6Q41934377-8EADCE65-A2CE-4DA9-831A-2489385BB038Q47547089-68F3B1A3-D4D1-4236-AD32-B86B7C909B16Q47832831-AA5C9C5C-BD53-436B-9321-59AC73F4A50DQ47923931-A9B2B7C7-0372-4AD6-84BB-23C6B15D9F39Q48091555-5A09CF77-F05A-4596-9E7F-5DCD4269D724Q50034057-EB9503CF-F51E-48C0-A37A-92F24A5CCDC9Q50100582-605C9663-EC90-458F-9467-8EA2DFFBF50EQ55008806-1E49F00F-3550-4D3F-BE5A-C31BD39F18ADQ55138887-2697554D-5C2B-4907-B23C-5035F7F9F489Q55216962-083271A1-7DE4-4B7F-ABA6-7EC44B8D78BCQ58707841-ABD5D92C-CF2C-430F-A27D-F0B68431DA91Q58750630-44B97D39-F9F5-4060-B4AD-EE558F458F21
P2860
Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Programmed death ligand 1 expr ...... cal and pathological features.
@en
type
label
Programmed death ligand 1 expr ...... cal and pathological features.
@en
prefLabel
Programmed death ligand 1 expr ...... cal and pathological features.
@en
P2093
P2860
P50
P356
P1433
P1476
Programmed death ligand 1 expr ...... ical and pathological features
@en
P2093
Alain Luciani
Charlotte Costentin
Cécile Charpy
Daniel Azoulay
Elie-Serge Zafrani
Fouad Lafdil
Giuliana Amaddeo
Julien Calderaro
Marion Mercey
P2860
P304
P356
10.1002/HEP.28710
P407
P577
2016-08-09T00:00:00Z